|Awarded On||August 20, 2014|
|Title||Optimizing Therapy for Glioblastoma Through Genomic Profiling of Treatment Failure|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||John de Groot|
|Cancer Sites||Brain and Other Nervous System|
Glioblastoma (GBM) are the most common and aggressive type of adult brain tumors. Despite the standard of care, concomitant radiation and temozolomide based chemotherapy treatment, disease relapse typically occurs within a year for most patients. Through ultra high throughput sequencing, the genetic DNA profile of GBM has been analyzed for the presence of abnormal molecular changes that might relate to the disease. The first goal of this grant is to utilize these methods to identify molecular changes that occur in GBM cells as a result of the treatment. Alterations that are detected after treatment but not before therapy may provide a basis for new types of treatment. Through computational a...